NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR(TM) in Head and Neck

[ASFN Admin]

RaDaR demonstrated 100% specificity in patients with no recurrence and 100% sensitivity in patients with clinical recurrenceFT MYERS, FL / ACCESSWIRE / February 11, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limited ("Inivata") has announced clinical validation data for its RaDaRTM liquid biopsy test in head and neck squamous

Continue reading...